|
Mutation Information
|
Mutation Site
|
V106I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
NNRTIs |
Literature Information
|
PubMed PMID
|
30352054
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
PloS one |
|
Title
|
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial. |
|
Author
|
Morales-Ramirez J,Bogner JR,Molina JM,Lombaard J,Dicker IB,Stock DA,DeGrosky M,Gartland M,Pene Dumitrescu T,Min S,Llamoso C,Joshi SR,Lataillade M |
|
Evidence
|
Non-NRTI (NNRTI) mutations, V106V/I and E138E/G, were detected in one participant each in the GSK3532795 60 mg and 120 mg arms.
|
|
|
HIV Mutation Detail Information